Evaluate ICU patient deterioration AI by FDA status, intended use, EHR and device data flow, alert burden, local validation, and escalation workflow.
Representative source image: official CLEW ICU product page.
Quick answer: ICU patient deterioration AI should be evaluated as high-risk clinical decision support or medical-device software. Match the tool to its cleared intended use, validate it locally, define who receives alerts, and monitor false positives, missed deterioration, response time, and equity after launch.
Who this guide is for
ICU leaders, tele-ICU programs, rapid response teams, CMIOs, patient-safety leaders, and hospital AI governance committees evaluating predictive surveillance.
What makes this workflow different
Predictive ICU surveillance is not a generic dashboard; it changes clinical attention, escalation timing, and patient-safety accountability.
What to verify before using it
Verify FDA, CE, UKCA, or local regulatory status for the exact prediction model and patient population.
Map every data source, including EHR feeds, bedside devices, monitors, labs, demographics, and command-center integrations.
Define alert routing, escalation thresholds, backup workflows, downtime procedures, and who is accountable for acting on predictions.
Run local validation for sensitivity, positive predictive value, low-risk classification, false negatives, alert fatigue, and subgroup performance.
Track post-go-live adoption, response time, override patterns, mortality or ICU-transfer claims, length of stay, and unintended workflow harm.
Risk level and safe use
Medical risk
High
Best first step
Write the workflow in one sentence, decide who reviews the AI output, and test with a small controlled pilot before expanding.
Recommended posture
Use AI as supervised workflow support. Verify sources, privacy, human review, and regulatory fit before relying on outputs.
Source-backed products for this workflow
These profiles are not rankings. They are starting points for checking vendor claims, privacy terms, FDA or regulatory posture, evidence, and workflow fit.
CLEW describes CLEW ICU as an AI-driven clinical surveillance platform for high-acuity care with FDA-cleared class II predictive models; FDA records list K233216 for the CLEWICU System as a medium-term adjunctive predictive cardiovascular indicator with a January 13, 2024 substantial-equivalence decision.
Best for
Hospitals evaluating predictive surveillance for high-acuity units where ICU teams can govern alert routing, escalation, and local performance monitoring.
First check
FDA 510(k) K233216 intended use, adult critical-care setting, product code, decision date, and any predetermined change-control plan boundaries.
Bayesian Health describes a real-time clinical intelligence platform that reads EHR signals, adapts to patient baselines, surfaces risk, guides clinicians inside workflows, and reports published and real-world outcome claims; FDA records list K250680 for the Bayesian Health Sepsis Flagging Device as a Class II software device to aid sepsis prediction or diagnosis.
Best for
Hospitals evaluating governed clinical AI for sepsis, deterioration, or other inpatient risk workflows where alerts need context, clinician trust, and performance monitoring.
First check
Whether the deployment uses the FDA-cleared Bayesian Health Sepsis Flagging Device K250680, another Bayesian module, or a broader clinical pathway workflow.
Prenosis describes Sepsis ImmunoScore as an FDA De Novo-authorized AI sepsis diagnostic and predictive tool that combines up to 22 patient parameters, biomarkers, vital signs, demographics, and EHR data; FDA records list DEN230036, and Roche navify materials describe cloud-based algorithm-suite deployment and intended-use boundaries.
Best for
Hospitals evaluating transparent sepsis risk stratification that combines clinical data and biomarkers with EMR-integrated review for suspected sepsis workflows.
First check
FDA De Novo DEN230036 intended use, patient eligibility, blood-culture-order requirement, 24-hour risk window, and prescription-use limits.
Mednition describes KATE as a clinical AI platform for emergency department triage, sepsis recognition, and clinical analytics that reads structured and unstructured EHR data; company materials describe KATE Sepsis as having FDA Breakthrough Device Designation, while FDA guidance explains that designation is not the same as marketing authorization.
Best for
Hospitals evaluating AI as a triage safety net for emergency nurses where alerts can be governed through ED, sepsis, nursing, quality, and informatics workflows.
First check
Which module is in scope: KATE Triage, KATE Sepsis, Clinical Data Engine, reporting dashboards, or retrospective cohort analytics.
Sources
6 official sources
Official source trail for this workflow
Open these vendor, documentation, privacy, or regulatory sources before relying on product claims, especially for FDA status, PHI handling, deployment model, and intended use.
Find the best AI for medical workflows by matching the tool to documentation, questions, diagnosis support, research, coding, billing, imaging, or practice operations.
Understand AI for medical diagnosis, including validation evidence, FDA status, clinical supervision, and why patient-specific diagnosis should not rely on general chatbots.
